Endocannabinoid system, stress and HPA axis.
Vincenzo Micale, Filippo Drago
European Journal of Pharmacology September 1, 2018 DOI: 10.1016/j.ejphar.2018.07.039 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The review argues that endocannabinoid system signaling is an important mediator of the interaction between HPA axis activity and stressful conditions, and that this interaction may be involved in the development of psychiatric disorders. It also states that how the ECS modifies stress hormone secretion is not fully understood. |
Abstract
The endocannabinoid system (ECS), which is composed of the cannabinoid receptors types 1 and 2 (CB1 and CB2) for marijuana's psychoactive ingredient ∆9-tetrahydrocannabinol (∆9-THC), the endogenous ligands (AEA and 2-AG) and the enzymatic systems involved in their biosynthesis and degradation, recently emerged as important modulator of emotional and non-emotional behaviors. In addition to its recreational actions, some of the earliest reports regarding the effects of Cannabis use on humans were related to endocrine system changes. Accordingly, the ∆9-THC and later on, the ECS signalling have long been known to regulate the hypothalamic-pituitary-adrenocortical (HPA) axis, which is the major neuroendocrine stress response system of mammals. However, how the ECS could modify the stress hormone secretion is not fully understood. Thus, the present article reviews current available knowledge on the role of the ECS signalling as important mediator of interaction between HPA axis activity and stressful conditions, which, in turn could be involved in the development of psychiatric disorders.
Citations in the library
Cited by 6
- Dose-related reductions in prefrontal recruitment during cognitive reappraisal following oral delta-9-tetrahydrocannabinol in posttraumatic stress disorder. Neuropsychopharmacology July 16, 2026
- Decoding the Toxicity of Synthetic Cannabinoids: From Receptor Activation to Multiorgan Dysfunction. Medicinal Research Reviews June 24, 2026
- The Brain Endocannabinoid System is Differentially Regulated in Male and Female Patients with First-Episode Psychosis Schizophrenia Bulletin April 10, 2026
- Phytocannabinoids and schizophrenia: Focus on adolescence as a critical window of enhanced vulnerability and opportunity for treatment. Pharmacological Research December 1, 2021
- Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacological Research February 2021
and 1 more in the library